The economic cost of dementia to Australia has been revealed in a new report which highlights the pressing need for greater research.
In the Alzheimer’s Australia report, it is estimated that dementia will cost A$14.7 billion ($11.3 billion) to the country in 2017, and a 5% reduction in the incidence of the condition would save A$5.7 billion.
As he welcomed the release of the report, Australia’s Minister for Aged Care, Ken Wyatt, said the government had committed A$200 million over five years to dementia research, an area where there have been some expensive failures in drug development globally.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze